A detailed history of D. E. Shaw & Co., Inc. transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 1,022,455 shares of MRSN stock, worth $2.27 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,022,455
Holding current value
$2.27 Million
% of portfolio
0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.23 - $2.25 $545,043 - $997,031
-443,125 Reduced 30.24%
1,022,455 $1.93 Million
Q2 2024

Aug 14, 2024

BUY
$2.0 - $4.45 $485,914 - $1.08 Million
242,957 Added 19.87%
1,465,580 $2.95 Million
Q1 2024

May 15, 2024

BUY
$2.16 - $5.94 $1.2 Million - $3.3 Million
555,240 Added 83.2%
1,222,623 $5.48 Million
Q4 2023

Feb 14, 2024

BUY
$1.11 - $2.34 $665,557 - $1.4 Million
599,601 Added 884.6%
667,383 $1.55 Million
Q3 2023

Nov 14, 2023

SELL
$1.06 - $3.91 $973,034 - $3.59 Million
-917,957 Reduced 93.12%
67,782 $86,000
Q2 2023

Aug 14, 2023

SELL
$3.08 - $9.55 $2.53 Million - $7.83 Million
-820,360 Reduced 45.42%
985,739 $3.24 Million
Q1 2023

May 15, 2023

SELL
$4.0 - $7.02 $2.12 Million - $3.72 Million
-529,840 Reduced 22.68%
1,806,099 $7.42 Million
Q4 2022

Feb 14, 2023

SELL
$5.65 - $7.86 $1.63 Million - $2.27 Million
-288,284 Reduced 10.99%
2,335,939 $13.7 Million
Q3 2022

Nov 14, 2022

BUY
$4.63 - $8.0 $2.99 Million - $5.17 Million
646,293 Added 32.68%
2,624,223 $17.7 Million
Q2 2022

Aug 15, 2022

SELL
$2.84 - $5.0 $320,738 - $564,680
-112,936 Reduced 5.4%
1,977,930 $9.14 Million
Q1 2022

May 16, 2022

BUY
$3.74 - $6.63 $5.41 Million - $9.59 Million
1,445,963 Added 224.21%
2,090,866 $8.34 Million
Q4 2021

Feb 14, 2022

BUY
$5.48 - $9.86 $3.27 Million - $5.88 Million
596,298 Added 1226.82%
644,903 $4.01 Million
Q3 2021

Nov 15, 2021

BUY
$8.56 - $14.47 $72,931 - $123,284
8,520 Added 21.25%
48,605 $458,000
Q2 2021

Aug 16, 2021

SELL
$13.28 - $18.07 $1.51 Million - $2.06 Million
-113,986 Reduced 73.98%
40,085 $544,000
Q1 2021

May 17, 2021

SELL
$15.31 - $26.52 $5.97 Million - $10.3 Million
-389,804 Reduced 71.67%
154,071 $2.49 Million
Q4 2020

Feb 16, 2021

SELL
$16.84 - $27.59 $3.5 Million - $5.73 Million
-207,851 Reduced 27.65%
543,875 $14.5 Million
Q3 2020

Nov 16, 2020

SELL
$16.2 - $25.7 $4.44 Million - $7.05 Million
-274,224 Reduced 26.73%
751,726 $14 Million
Q2 2020

Aug 14, 2020

BUY
$5.24 - $23.4 $5.25 Million - $23.5 Million
1,002,801 Added 4331.94%
1,025,950 $24 Million
Q1 2020

May 15, 2020

SELL
$4.41 - $9.28 $551,241 - $1.16 Million
-124,998 Reduced 84.37%
23,149 $135,000
Q4 2019

Feb 14, 2020

SELL
$1.45 - $6.73 $135,457 - $628,709
-93,419 Reduced 38.67%
148,147 $848,000
Q3 2019

Nov 14, 2019

SELL
$1.54 - $4.2 $5,005 - $13,650
-3,250 Reduced 1.33%
241,566 $382,000
Q2 2019

Aug 14, 2019

BUY
$3.84 - $6.4 $499,983 - $833,305
130,204 Added 113.6%
244,816 $991,000
Q1 2019

May 15, 2019

BUY
$3.51 - $7.3 $402,288 - $836,667
114,612 New
114,612 $603,000
Q1 2018

May 15, 2018

SELL
$13.56 - $18.48 $230,981 - $314,788
-17,034 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$14.95 - $19.9 $254,658 - $338,976
17,034
17,034 $280,000

Others Institutions Holding MRSN

About Mersana Therapeutics, Inc.


  • Ticker MRSN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,169,296
  • Market Cap $216M
  • Description
  • Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...
More about MRSN
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.